Pradžia › Limfoma › Merilendas
Limfoma klinikiniai tyrimai Merilendas
21 tyrimai dėl Limfoma ieško dalyvių vietose Merilendas.
Miestai Merilendas
Oficialus tyrimo tekstas (anglų kalba)
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviai2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT03258567Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviaiStebimasis tyrimas
Amžius 3 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT01441089CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviai1/2 fazė
Amžius nuo 3 iki 39 · Visoms lytims · Atnaujinta 2026-09-30 · NCT05442515Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-09-28 · NCT00006518Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 110 · Visoms lytims · Atnaujinta 2026-09-28 · NCT00923507Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-09-28 · NCT03223610Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Renkami dalyviaiAnkstyvoji 1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-24 · NCT06398457A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Maryland Oncology Hematology, Silver Spring
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT07221500Collection of Tissue Samples for Cancer Research
- Johns Hopkins University, Baltimore
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviaiStebimasis tyrimas
2 Months · Visoms lytims · Atnaujinta 2026-09-16 · NCT00900198CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Renkami dalyviai1/2 fazė
12 Months – 21 Years · Visoms lytims · Atnaujinta 2026-09-11 · NCT04870944Sample Collection and Tracking for the Developmental Therapeutics Clinic
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-09-08 · NCT03269578Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Bethesda
Renkami dalyviai3 fazė
Amžius nuo 18 iki 18 · Visoms lytims · Atnaujinta 2026-09-08 · NCT07509151Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
- Walter Reed National Military Medical Center, Bethesda
Renkami dalyviaiStebimasis tyrimas
Amžius 4 ir vyresni · Visoms lytims · Atnaujinta 2026-09-03 · NCT07652580Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius 5 ir vyresni · Visoms lytims · Atnaujinta 2026-08-31 · NCT05237986Vaccine Responses in Patients With B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviai4 fazė
Amžius nuo 18 iki 90 · Visoms lytims · Atnaujinta 2026-08-04 · NCT05170399DALY II USA/ MB-CART2019.1 for DLBCL
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-13 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institute of Health, Bethesda
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-02 · NCT05131022Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-01 · NCT05663502Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-05-27 · NCT06856226Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-05-18 · NCT01790152A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-20 · NCT04830137Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.